Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$5.89 -2.6%	$6.32	$5.14 ▼ $11.16	$453.61M	0.87	2.56 million shs	1.58 million shs
GPCR Structure Therapeutics	$20.34 -3.4%	$24.71	$19.39 ▼ $62.74	$1.17B	-2.37	800,231 shs	734,014 shs
LLY Eli Lilly and Company	$852.35 -1.5%	$837.36	$711.40 ▼ $972.53	$808.17B	0.34	3.15 million shs	2.59 million shs
NVO Novo Nordisk A/S	$73.57 -2.3%	$83.16	$73.80 ▼ $148.15	$330.15B	0.42	5.43 million shs	8.86 million shs
PFE Pfizer	$25.56 -2.2%	$26.15	$24.48 ▼ $31.54	$144.96B	0.61	45.19 million shs	46.03 million shs
VKTX Viking Therapeutics	$27.98 -4.4%	$30.84	$24.41 ▼ $89.10	$3.14B	0.9	4.45 million shs	2.42 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+4.44%	+1.34%	-5.91%	-19.87%	-33.37%
GPCR Structure Therapeutics	+0.38%	-3.40%	-11.16%	-25.49%	-50.91%
LLY Eli Lilly and Company	+3.16%	+4.90%	-0.94%	+8.83%	+12.37%
NVO Novo Nordisk A/S	-2.05%	-6.18%	-14.49%	-13.81%	-41.52%
PFE Pfizer	-0.27%	+0.26%	-0.70%	-2.27%	-4.48%
VKTX Viking Therapeutics	+1.14%	-1.84%	-14.06%	-30.86%	-57.90%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	2.8263 of 5 stars	3.4	2.0	0.0	0.0	2.7	3.3	0.6
GPCR Structure Therapeutics	2.1027 of 5 stars	3.5	1.0	0.0	0.0	2.7	1.7	0.6
LLY Eli Lilly and Company	4.6221 of 5 stars	2.4	3.0	3.3	4.0	2.9	2.5	1.9
NVO Novo Nordisk A/S	4.6937 of 5 stars	4.4	4.0	1.7	0.0	1.9	0.0	4.4
PFE Pfizer	4.9844 of 5 stars	3.3	3.0	4.2	4.2	2.8	3.3	3.1
VKTX Viking Therapeutics	4.4842 of 5 stars	4.5	2.0	0.0	4.7	2.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.89	Moderate Buy	$20.83	253.71% Upside
GPCR Structure Therapeutics	3.00	Buy	$81.29	299.63% Upside
LLY Eli Lilly and Company	2.85	Moderate Buy	$1,009.72	18.46% Upside
NVO Novo Nordisk A/S	2.80	Moderate Buy	$145.25	97.43% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	24.89% Upside
VKTX Viking Therapeutics	3.00	Buy	$97.67	249.06% Upside

Current Analyst Ratings Breakdown

Latest PFE, NVO, LLY, VKTX, ALT, and GPCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/18/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/14/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
3/13/2025	NVO Novo Nordisk A/S	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/11/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/6/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$1,146.00
3/5/2025	LLY Eli Lilly and Company	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$970.00 ➝ $1,100.00
3/3/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/3/2025	NVO Novo Nordisk A/S	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold

(Data available from 3/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	22,680.62	N/A	N/A	$2.75 per share	2.14
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$9.77 per share	N/A
LLY Eli Lilly and Company	$45.04B	17.94	$13.90 per share	61.34	$15.05 per share	56.63
NVO Novo Nordisk A/S	$290.40B	1.14	$3.41 per share	21.57	$4.64 per share	15.86
PFE Pfizer	$63.63B	2.28	$4.01 per share	6.38	$15.81 per share	1.62
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$3.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.45M	-$1.34	N/A	N/A	N/A	-199,076.92%	-55.81%	-50.60%	5/8/2025 (Estimated)
GPCR Structure Therapeutics	-$89.62M	-$0.79	N/A	N/A	N/A	N/A	-16.37%	-15.68%	5/8/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$11.71	72.79	27.39	1.40	23.51%	85.24%	16.19%	4/29/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.29	22.36	15.79	0.90	34.81%	84.68%	26.29%	5/1/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	18.13	8.44	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.00	N/A	N/A	N/A	N/A	-11.93%	-11.57%	4/23/2025 (Estimated)

Latest PFE, NVO, LLY, VKTX, ALT, and GPCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/27/2025	Q4 2024	ALT Altimmune	-$0.34	-$0.33	+$0.01	-$0.33	$0.00 million	$0.01 million
2/27/2025	Q4 2024	GPCR Structure Therapeutics	-$0.23	-$0.22	+$0.01	-$0.22	N/A	N/A
2/6/2025	Q4 2024	LLY Eli Lilly and Company	$5.45	$5.32	-$0.13	$4.88	$13.42 billion	N/A
2/5/2025	Q4 2024	NVO Novo Nordisk A/S	$0.88	$0.91	+$0.03	$0.91	N/A	N/A
2/5/2025	Q4 2024	VKTX Viking Therapeutics	-$0.27	-$0.32	-$0.05	-$0.32	N/A	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.00	0.70%	+15.21%	51.24%	11 Years
NVO Novo Nordisk A/S	$1.57	2.13%	+25.26%	47.72%	N/A
PFE Pfizer	$1.72	6.73%	+2.50%	121.99%	16 Years
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest PFE, NVO, LLY, VKTX, ALT, and GPCR Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/5/2025	NVO Novo Nordisk A/S	semi-annual	$0.7874	1.2%	3/31/2025	3/31/2025	4/8/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	16.87	16.87
GPCR Structure Therapeutics	N/A	27.63	27.63
LLY Eli Lilly and Company	2.00	1.15	0.97
NVO Novo Nordisk A/S	0.62	0.74	0.55
PFE Pfizer	0.63	1.00	0.73
VKTX Viking Therapeutics	N/A	36.47	36.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
GPCR Structure Therapeutics	91.78%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
PFE Pfizer	68.36%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
GPCR Structure Therapeutics	9.43%
LLY Eli Lilly and Company	0.13%
NVO Novo Nordisk A/S	0.07%
PFE Pfizer	0.06%
VKTX Viking Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	77.01 million	68.21 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.86 million	Optionable
LLY Eli Lilly and Company	39,000	948.17 million	948.08 million	Optionable
NVO Novo Nordisk A/S	54,400	4.49 billion	4.48 billion	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
VKTX Viking Therapeutics	20	112.25 million	106.20 million	Optionable

PFE, NVO, LLY, VKTX, ALT, and GPCR Headlines

Recent News About These Companies

Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 3.4% - Here's What Happened

March 25 at 3:41 PM | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Pier Capital LLC

March 25 at 6:38 AM | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by EFG Asset Management North America Corp.

March 25 at 5:50 AM | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know

March 24 at 6:50 PM | zacks.com

Viking Therapeutics (NASDAQ:VKTX) Stock Price Up 1.5% - Should You Buy?

March 24 at 1:53 PM | marketbeat.com

Emerald Advisers LLC Has $76,000 Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

March 24 at 5:45 AM | marketbeat.com

Virtu Financial LLC Makes New $1.72 Million Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)

March 23 at 5:25 AM | marketbeat.com

Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly

March 23 at 4:43 AM | fool.com

Amundi Sells 30,538 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

March 23 at 3:19 AM | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Rating of "Buy" by Analysts

March 23 at 2:35 AM | marketbeat.com

MarketBeat Week in Review – 03/17 - 03/21 (VKTX)

March 22 at 7:00 AM | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Trading Down 0% - Time to Sell?

March 21, 2025 | marketbeat.com

Magnetar Financial LLC Acquires New Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX)

March 21, 2025 | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 1% - Here's What Happened

March 20, 2025 | marketbeat.com

1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street

March 20, 2025 | fool.com

Tocqueville Asset Management L.P. Invests $814,000 in Viking Therapeutics, Inc. (NASDAQ:VKTX)

March 20, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Holdings Raised by Royce & Associates LP

March 20, 2025 | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 0.6% - Here's Why

March 19, 2025 | marketbeat.com

Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy?

March 19, 2025 | fool.com

Viking Therapeutics (NASDAQ:VKTX) Shares Down 3.7% - Time to Sell?

March 18, 2025 | marketbeat.com

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

March 18, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Volatility Is Back: 3 Stocks To Cushion the S&P 500's Swings
By Gabriel Osorio-Mazilli | February 27, 2025
View Volatility Is Back: 3 Stocks To Cushion the S&P 500's Swings
Cybersecurity Stocks Surge as $32B Deal Reshapes the Industry
By Gabriel Osorio-Mazilli | March 21, 2025
View Cybersecurity Stocks Surge as $32B Deal Reshapes the Industry
BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
Intel Foundry’s Moment of Truth: Will 18A Deliver?
By Jeffrey Neal Johnson | March 6, 2025
View Intel Foundry’s Moment of Truth: Will 18A Deliver?
Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
By Chris Markoch | March 21, 2025
View Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?

PFE, NVO, LLY, VKTX, ALT, and GPCR Company Descriptions

Altimmune NASDAQ:ALT

$5.89 -0.16 (-2.64%)

Closing price 04:00 PM Eastern

Extended Trading

$5.88 -0.01 (-0.25%)

As of 04:47 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Structure Therapeutics NASDAQ:GPCR

$20.34 -0.71 (-3.37%)

Closing price 04:00 PM Eastern

Extended Trading

$20.78 +0.45 (+2.19%)

As of 04:39 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Eli Lilly and Company NYSE:LLY

$852.35 -12.55 (-1.45%)

Closing price 03:58 PM Eastern

Extended Trading

$853.60 +1.25 (+0.15%)

As of 04:49 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$73.57 -1.76 (-2.34%)

Closing price 03:58 PM Eastern

Extended Trading

$73.83 +0.27 (+0.36%)

As of 04:50 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer NYSE:PFE

$25.56 -0.58 (-2.22%)

Closing price 03:58 PM Eastern

Extended Trading

$25.60 +0.04 (+0.16%)

As of 04:50 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Viking Therapeutics NASDAQ:VKTX

$27.98 -1.30 (-4.44%)

Closing price 04:00 PM Eastern

Extended Trading

$28.27 +0.29 (+1.02%)

As of 04:47 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFE, NVO, LLY, VKTX, ALT, and GPCR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFE, NVO, LLY, VKTX, ALT, and GPCR Earnings

Compare Dividends

Latest PFE, NVO, LLY, VKTX, ALT, and GPCR Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFE, NVO, LLY, VKTX, ALT, and GPCR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PFE, NVO, LLY, VKTX, ALT, and GPCR Company Descriptions

Altimmune NASDAQ:ALT

Structure Therapeutics NASDAQ:GPCR

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

Pfizer NYSE:PFE

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools